ROVI's activity focuses primarily on the manufacture and marketing of pharmaceutical products and contract manufacturing services. It has its corporate headquarters in Spain, where it carries on the entirety of its manufacturing services and research and development activities, as well as a large part of its marketing operations. Currently, it has seven fully-consolidated manufacturing plants, two of which specialise in the fill-finish of injectable products –vials and syringes– (Madrid and San Sebastián de los Reyes), while a third specialises in the manufacture of solid oral forms and is a packaging excellence centre (Alcalá de Henares). A fourth plant engages in the manufacture of Risperidone ISM® (Madrid) and a fifth is a pilot plant engaged in R&D (Madrid). Finally, the other two facilities are engaged in producing active substance (low-molecular-weight heparins) in Granada and Escúzar, respectively.

Over recent decades, ROVI’s internationalisation has advanced and it now has subsidiaries in Portugal, Germany, France, the United Kingdom, Italy and Poland. This international presence is due to the implementation of a growth-oriented strategy to seek opportunities to expand the business and diversify risks.

In 2022 –the last full financial year–, the company obtained revenue of 817.7 million euros, with the contract manufacturing business line growing 52% to 403.5 million euros. Additionally, ROVI’s EBITDA rose 37% in 2022, totalling 278.9 million euros. Net profit increased 30% to 199.77 million euros.

At the end of 2022, Laboratorios Farmacéuticos ROVI had a total of 1993 employees, 53% of whom were women, while 47% were men. Most of them, 89%, held permanent contracts, a 12 percentage point improvement in comparison with 2021.

ROVI’s three key pillars

The company’s economic activity is based on three key pillars: specialty pharmaceuticals, contract manufacturing and R&D&I investment.

First, ROVI has a portfolio of over 40 of its own and licensed products. This makes the specialty pharmaceutical area one of ROVI’s large pillars of growth. The products are indicated for the treatment and diagnosis of different complaints in nine therapeutic areas: cardiology, diagnostic imaging contrast agents, endocrinology, anaesthesia/pain relief, urology, primary healthcare, osteoarticular/women’s healthcare, central nervous system and respiratory.

The second pillar of growth is contract manufacturing, derived from the high manufacturing capacity available at ROVI’s facilities, which allows this business line to cover a wide variety of services (compounding, filling, inspection, labelling, packaging, blister packaging, installation of safety devices and serialisation) in an extensive range of forms (prefilled syringes, vials, tablets and sachets).

Research, development and innovation work is ROVI’s third pillar of growth. Its research portfolio concentrates on three main areas: its innovative drug-release technology, ISM®; the glycomics area; and medical devices, focusing on multilayer technologies for urethral catheters.

In all its business areas, ROVI endeavours to contribute to both improving health through its activities and responding to the social and environmental needs that exist. Therefore, the company aims for its economic development to be compatible with its conduct in respect of ethical, social, labour and environmental issues and respect for human rights.

ROVI holds a commitment to contribute to the progress of society. For this reason, it works in accordance with sustainable environmental, social and corporate governance goals, action plans and indicators. In 2022, its performance in this respect placed ROVI as the leader among the pharmaceutical companies rated by Sustainalytics, an independent company which is a global leader in ESG and corporate governance research, rating and analysis.